Press Releases

07.05.2019

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

07.01.2019

Pfizer Completes Acquisition of Therachon

07.01.2019

Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis

06.28.2019

Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension

06.28.2019

Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)

06.28.2019

Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

06.27.2019

Scott Gottlieb Elected to Pfizer’s Board of Directors

06.27.2019

Pfizer Declares Third-Quarter 2019 Dividend

06.21.2019

European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

06.18.2019

Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

06.17.2019

Pfizer to Acquire Array BioPharma

06.12.2019

Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor